287_63 Apr 2026

This molecule was part of a large library of triazole-modified alginates developed by researchers at MIT and Boston Children's Hospital. The goal was to find a coating that would allow implanted medical devices or encapsulated cells (like those used for Type 1 Diabetes treatment) to function inside the body without being attacked by the immune system. Key Findings for 287_63

: It is a core component of U.S. Patent 10,898,443 and U.S. Patent 11,337,930 , which describe methods for making and using these modified alginates for cell therapy. ( 12 ) United States Patent - Googleapis.com 287_63

"287_63" refers to a specific chemical identifier—specifically —used in groundbreaking research on modified alginate polymers to prevent the foreign body response (fibrosis) in medical implants. Research Context This molecule was part of a large library

: In animal models, 287_63 was identified as one of the top-performing "anti-fibrotic" materials. It significantly reduced the formation of scar tissue around implants. Patent 10,898,443 and U

: Highly cited papers in Nature Medicine and Nature Biotechnology (circa 2016) by the Anderson and Langer labs.

: It is primarily discussed in the context of encapsulated islet cell transplantation . By coating insulin-producing cells in 287_63, researchers successfully restored blood sugar control in mice for long periods without using immunosuppressants. Patent and Publication Detailed write-ups and data on 287_63 can be found in:

: It is a triazole-based modification of alginate, specifically created through "click chemistry" to change the surface properties of the polymer.